Cessation of Gonadotropin-Releasing Hormone Antagonist on Triggering Day: An Alternative Method for Flexible Multiple-Dose Protocol.
10.3346/jkms.2009.24.2.262
- Author:
Hye Jin CHANG
1
;
Jung Ryeol LEE
;
Byung Chul JEE
;
Chang Suk SUH
;
Seok Hyun KIM
Author Information
1. Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, Korea. suhcs@snu.ac.kr
- Publication Type:Original Article ; Controlled Clinical Trial
- Keywords:
GnRH Antagonist;
hCG Administration;
Oocyte Maturation;
Fertilization;
Ovulation Induction;
Cetrorelix
- MeSH:
Adult;
Chorionic Gonadotropin/administration & dosage;
Drug Administration Schedule;
Estradiol/blood;
Female;
Fertilization in Vitro;
Follicle Stimulating Hormone/administration & dosage/blood;
Gonadotropin-Releasing Hormone/*antagonists & inhibitors;
Hormone Antagonists/*administration & dosage;
Humans;
Ovulation Induction/*methods;
Recombinant Proteins/therapeutic use;
Retrospective Studies
- From:Journal of Korean Medical Science
2009;24(2):262-268
- CountryRepublic of Korea
- Language:English
-
Abstract:
This study was performed to analyze retrospectively outcomes of stimulated in vitro fertilization (IVF) cycles where the gonadotropin-releasing hormone (GnRH) antagonist was omitted on ovulation triggering day. A total of 92 consecutive IVF cycles were included in 65 women who are undergoing ovarian stimulation with recombinant FSH. A GnRH antagonist, cetrorelix 0.25 mg/day, was started when leading follicle reached 14 mm in diameter until the day of hCG administration (Group A, 66 cycles) or until the day before hCG administration (Group B, 26 cycles). The duration of ovarian stimulation, total dose of gonadotropins, serum estradiol levels on hCG administration day, and the number of oocytes retrieved were not significantly different between the two groups. The total dose of GnRH antagonist was significantly lower in Group B compared to Group A (2.7+/-0.8 vs. 3.2+/-0.9 ampoules). There was no premature luteinization in the subjects. The proportion of mature oocytes (71.4% vs. 61.7%) and fertilization rate of mature (86.3+/-19.7% vs. 71.8+/-31.7%) was significantly higher in Group B. There were no significant differences in embryo quality and clinical pregnancy rates. Our results suggest that cessation of the GnRH antagonist on the day of hCG administration during a flexible multiple-dose protocol could reduce the total dose of GnRH antagonist without compromising IVF results.
